forzinity: independent research notes on the elamipretide record

forzinity is a personal research site about forzinity — the elamipretide (ss-31) product that received FDA accelerated approval in September 2025. These pages summarize the published record: what the molecule is and how it is documented to work, what the clinical trials actually measured, what the label and safety data say, and what the cost and market-access picture looks like. We sell nothing, link no sellers, and give no medical advice — every page is an evidence-graded summary of public documents.